GlassScriptPhysician profile
Syed Rafique
NPI 1871607598
$17,299.76
in general payments reported to CMS, 2019-2025
69 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,367 · 2020: $666 · 2021: $2,633 · 2022: $2,814 · 2023: $2,773 · 2024: $3,031 · 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,156 · Education: $413 · Long Term Medical Supply Or Device Loan: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,155.83 |
| Education | $413.19 |
| Long Term Medical Supply Or Device Loan | $249.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,347.32 | 2019-2025 | |
| Gilead Sciences, INC. | $1,022.95 | 2021-2025 | Trodelvy |
| Pfizer INC. | $944.47 | 2019-2025 | |
| Janssen Biotech, INC. | $878.22 | 2019-2025 | Erleada, Rybrevant, Balversa |
| E.R. Squibb & Sons, L.L.C. | $806.84 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $738.66 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $710.64 | 2019-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $587.21 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Exelixis INC. | $534.65 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $519.95 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Astrazeneca Pharmaceuticals LP | $515.00 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $494.95 | 2019-2025 | |
| Amgen INC. | $469.31 | 2019-2023 | Kyprolis |
| Adaptive Biotechnologies Corporation | $404.19 | 2023-2025 | Clonoseq |
| Genentech USA, INC. | $383.42 | 2019-2025 | Tecentriq, Polivy, Itovebi |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $320.53 | 2019-2025 | |
| Genzyme Corporation | $301.27 | 2019-2025 | |
| Lilly USA, LLC | $288.72 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $249.69 | 2019-2025 | Fruzaqla, Ninlaro, Iclusig |
| Rigel Pharmaceuticals, INC. | $246.13 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Kite Pharma, INC. | $230.83 | 2021-2023 | Yescarta |
| Glaxosmithkline, LLC. | $204.50 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $204.08 | 2019-2023 | Imbruvica, Epkinly |
| Seagen INC. | $194.13 | 2019-2023 | Adcetris |
| Sanofi-Aventis U.S. LLC | $192.46 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $139.20 | 2022-2025 | Libtayo |
| Beigene USA, INC. | $136.59 | 2021-2024 | Brukinsa |
| Puma Biotechnology, INC. | $128.17 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $116.42 | 2022-2025 | |
| Sobi, INC | $103.67 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $92.65 | 2019-2020 | |
| Stemline Therapeutics INC. | $90.50 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $90.40 | 2022-2025 | Enhertu, Datroway |
| Array Biopharma INC | $89.57 | 2019-2024 | Braftovi, Mektovi, Lorbrena |
| Emd Serono, INC. | $82.02 | 2022-2024 | Bavencio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.44 | 2022-2025 | Gilotrif |
| Pharmacosmos Therapeutics INC. | $77.53 | 2023-2024 | Monoferric, Cosela |
| Spectrum Pharmaceuticals INC. | $75.32 | 2023-2025 | Rolvedon |
| Taiho Oncology, INC. | $73.24 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $73.13 | 2021-2025 | |
| Sanofi US Services INC. | $72.95 | 2025 | |
| Verastem, INC. | $66.76 | 2019 | |
| Coherus Oncology, INC. | $60.92 | 2021-2025 | Loqtorzi |
| Deciphera Pharmaceuticals INC. | $57.05 | 2023-2025 | Qinlock, Romvimza |
| Global Blood Therapeutics, INC. | $56.90 | 2022 | |
| Karyopharm Therapeutics INC. | $55.38 | 2025 | Xpovio |
| G1 Therapeutics, INC. | $45.99 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $45.45 | 2019-2024 | Onivyde, Tazverik |
| Mirati Therapeutics, INC. | $42.06 | 2023-2024 | Krazati |
| Tesaro, INC. | $38.57 | 2019 | |
| Alexion Pharmaceuticals, INC. | $29.13 | 2019-2024 | Ultomiris |
| Clovis Oncology, INC. | $28.78 | 2020 | |
| Pharmaessentia USA Corporation | $28.42 | 2024 | Besremi |
| Beone Medicines USA, INC. | $21.47 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $20.83 | 2024 | |
| Caris Mpi, INC. | $20.42 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $20.28 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.45 | 2025 | Myrisk |
| Novocure INC. | $17.37 | 2024 | Optune Lua (Novottf-200t) |
| Apellis Pharmaceuticals, INC. | $16.95 | 2023 | Empaveli |
| Partner Therapeutics, INC. | $16.13 | 2019 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Morphosys, US INC. | $14.74 | 2021 | |
| Servier Pharmaceuticals LLC | $14.32 | 2021 | |
| Genmab U.S., INC. | $13.61 | 2023 | Epkinly |
| Acceleron Pharma, INC. | $12.59 | 2021 | |
| Dendreon Pharmaceuticals LLC | $12.41 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rafique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.